Bharat Biotech International Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
- Paid Up Capital ₹ 13.03 Cr
- Company Age 28 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 251.50 Cr
- Satisfied Charges ₹ 105.50 Cr
About Bharat Biotech International
Bharat Biotech International Limited (BBIL) is a Public Limited Indian Non-Government Company incorporated in India on 15 February 1996 and has a history of 28 years and 11 months. Its registered office is in Hyderabad, Telangana.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 13.03 Cr.
The company currently has active open charges totaling ₹251.50 Cr. The company has closed loans amounting to ₹105.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Bharat Biotech International Limited India are Srinivas Tadepally as CFO and Yedlapati Darsini as Company Secretary. Krishna Ella, Suchitra Ella, Velagapudi Dutt, and Four other members serve as directors at the Company.
Company Details
- LocationHyderabad, Telangana
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TG1996PLC023232
- Company No.
023232
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Feb 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Bharat Biotech International Limited offer?
Bharat Biotech International Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Digestive Drugs, Immunization & Vaccination Drugs, Infant Vaccines, Healthcare Products & Aids, Health Drinks, Injectable Products, Tetanus Vaccine, Photo Frame, Wooden Photo Frames.
Who are the key members and board of directors at Bharat Biotech International?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suchitra Ella  | Managing Director | 25-Sep-2007 | Current |
| Srinivas Tadepally | CFO | 06-Jan-2015 | Current |
| Yedlapati Darsini | Company Secretary | 11-May-2022 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Krishna Ella | Whole-Time Director | 25-Sep-2007 | Current |
| Velagapudi Dutt | Director | 20-Mar-2020 | Current |
| Melappati Chakravarthy | Director | 26-Jul-2022 | Current |
Sai Devarajulu  | Whole-Time Director | 02-Sep-2020 | Current |
| Prathivadibhayankaram Rajagopalan | Director | 30-Sep-1998 | Current |
| Krishna Vadrevu | Whole-Time Director | 28-Dec-2011 | Current |
Financial Performance of Bharat Biotech International.
Enhance accessibility to Bharat Biotech International's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Bharat Biotech International?
In 2021, Bharat Biotech International had a promoter holding of 78.94% and a public holding of 21.06%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rcc Laboratories India Private LimitedSuchitra Ella and Sai Devarajulu are mutual person
Innova Agri Bio Park Private LimitedSai Devarajulu is a mutual person
Ella FoundationKrishna Ella and Suchitra Ella are mutual person
Dcm Shriram Industries LimitedVelagapudi Dutt is a mutual person
Chiron Behring Vaccines Private LimitedSai Devarajulu, Srinivas Tadepally and 1 more are mutual person
Chennai Willingdon Corporate FoundationVelagapudi Dutt is a mutual person
Charges (Loans)
₹251.50 Cr
₹105.50 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 176.00 Cr
- Hdfc Bank Limited : 50.00 Cr
- Citibank N.A : 25.00 Cr
- Centre For Tachnology Development : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jul 2014 | Hdfc Bank Limited | ₹50.00 Cr | Open |
| 28 Mar 2013 | Citibank N.A | ₹25.00 Cr | Open |
| 30 Nov 1998 | State Bank Of India | ₹176.00 Cr | Open |
| 07 Apr 1998 | Centre For Tachnology Development | ₹5.00 M | Open |
| 30 Jul 2010 | Export-Import Bank Of India | ₹50.00 Cr | Satisfied |
How Many Employees Work at Bharat Biotech International?
Bharat Biotech International has a workforce of 1286 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bharat Biotech International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bharat Biotech International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
